Claims for Patent: 12,023,325

Summary for Patent: 12,023,325

Title:	Methods of treating gastrointestinal stromal tumors
Abstract:	The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Inventor(s):	Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Assignee:	Deciphera Pharmaceuticals LLC
Application Number:	US18/500,650
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,023,325
Patent Claims:	1. A method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising: orally administering to the patient a 150 mg a once daily or twice daily dose of ripretinib, wherein the patient has previously been administered imatinib before administration of the ripretinib, and wherein the treatment provides more than 3 months of progression free survival in patients as determined by mRECIST 1.1, after at least one cycle of 42 days of the daily ripretinib administration. 2. The method of claim 1, wherein the patient has been previously administered three or more kinase inhibitors, including the imatinib, before administration of the ripretinib. 3. The method of claim 2, wherein the previously administered three or more kinase inhibitors are each selected from imatinib, sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatalanib, and crenolanib. 4. The method of claim 2, wherein the patient has been previously administered 4 or more lines of therapy. 5. The method of claim 1, comprising orally administering to the patient a 150 mg a once daily dose of ripretinib, wherein the daily dose is three tablets each comprising 50 mg ripretinib. 6. The method of claim 1, wherein the treatment provides more than 6 months of progression free survival in patients, as determined by mRECIST 1.1, after at least ten cycles of 42 days of the daily ripretinib administration.